Brief: Transgene Says AstraZeneca Terminates Oncolytic Virus R&D Collaboration

Transgene SA

05/05/2023 06:46

May 5 (Reuters) - Transgene SA  TRNG.PA :
    * COMPANY HAS BEEN INFORMED BY ASTRAZENECA OF ITS DECISION
TO
TERMINATE ITS ONCOLYTIC VIRUS RESEARCH AND DEVELOPMENT
COLLABORATION
    * TRANSGENE WILL REGAIN GLOBAL RIGHTS TO ONCOLYTIC VIRUS
DRUG
CANDIDATE THAT WAS IN-LICENSED BY ASTRAZENECA IN DECEMBER 2021
    * THIS DECISION HAS LIMITED IMPACT ON TRANSGENE'S FINANCIAL
GUIDANCE. COMPANY CONFIRMS ITS FINANCIAL VISIBILITY UNTIL EARLY
2024
    * DECISION WAS MADE BY ASTRAZENECA FOLLOWING A STRATEGIC
REVIEW OF
ITS PIPELINE

Source text for Eikon:  ID:nBw3qZtDJa 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))